•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million (USD23 million) from the Brazilian government as part of the Parcerias para o Desenvolvimento Produtivo (PDP). This initiative, co-promoted by domestic companies in Brazil and Brazilian Ministry of Health affiliated enterprises, aims to secure the…
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a Phase III clinical study for GZR4, its Category 1 therapeutic biologic product. GZR4 is an investigational ultra-long-acting insulin designed for once-per-week subcutaneous injection to treat diabetes. Drug ProfileGZR4 aims to provide a convenient…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation of results from the Phase IIb study for its glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18, at ObesityWeek 2024. The drug is administered once per week and targets the obese or overweight Chinese population. Study Design…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of a Phase I clinical study for GLR1023, a biosimilar candidate to Novartis’ Cosentyx (secukinumab). The company has recently dosed the first patient in the trial, which is focused on evaluating the safety and efficacy of…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase I clinical study for its insulin aspart 30 injection, a biosimilar version of Novo Nordisk (NYSE: NVO)’s pre-mixed NovoMix 30 used in…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has received registration approval from Algerian authorities for two of its insulin products: the insulin aspart injection pre-filled pen and the insulin aspart 30 injection pre-filled pen. These products are slated to be manufactured locally by…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of results from a Phase Ib/IIa study for GZR18, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, at the American Diabetes Association’s (ADA’s) 84th Scientific Sessions. The study evaluated GZR18’s efficacy in weight reduction for obese/overweight Chinese…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has received marketing approval for its insulin glargine pre-filled pen in Mexico. This marks the company’s first marketing authorization as a holder (MAH) in the Mexican market. Insulin glargine, a long-acting insulin analogue that requires daily…
•
Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a significant year-on-year (YOY) increase of 52.31% in revenues, reaching RMB 2.61 billion (USD 360 million). The Chinese pharmaceutical company also turned profitable, with net profits amounting to RMB 340 million (USD 46.92 million). The company’s…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a leading Chinese pharmaceutical company, has announced the commencement of dosing in a Phase I clinical study for its investigational GLP-1 receptor agonist, GZR18 tablets. This oral formulation is designed to target GPRC5D, BCMA, and CD3, and is intended to treat patients with recurrent…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has received marketing approval from Bolivia’s Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) for its Insulin Aspart (cartridge bottle). Insulin Aspart, a rapid-acting insulin analogue, begins to take effect within 10-20 minutes of subcutaneous…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of the first patient in a Phase II clinical study for its Category 1 therapeutic biologic product, GZR4. GZR4 is an investigational ultra-long-acting insulin designed for once-per-week subcutaneous injection to treat diabetes. Design and Objectives of…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has received marketing approval from Bolivia’s State Agency of Drugs and Health Technologies (AGEMED) for its insulin glargine product, which comes in a pre-filled format. Insulin Glargine: A Long-Acting Insulin AnalogueInsulin glargine is a long-acting insulin…
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB 814 million (USD 111.4 million) through a private placement. The funds raised will be used as supplementary working capital to support the company’s operations and strategic initiatives. Shareholding Structure and Company ValuationMr. Gan Zhongru, the…
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 therapeutic biologic product GZR4 for the treatment of diabetes. Product DetailsThe half-life of long-acting basal insulin analogs currently on the market ranges from…
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a Phase II clinical study for its Category 1 biologic product GZR18, a novel glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-weekly administration. Study DetailsThe Phase Ib/IIb study will evaluate the safety, tolerability, pharmacokinetics,…
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product GZR4 has received clinical trial approval for treating diabetes. GZR4 is an ultra-long-acting insulin designed for once-weekly subcutaneous injection, addressing the need for more stable and convenient diabetes management. Product ProfileCurrent long-acting basal insulin analogs…
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a China-based Phase I clinical study for its drug candidate GZR101. The first-in-human study aims to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of the GZR101 injection and its component GZR33. Drug Details and…